Amgen Wins FDA Approval for IMDELLTRA Monitoring Time Cut

Amgen shares rose 0.03% to $377.45 in pre-market trading on NasdaqGS after the FDA approved an update to the IMDELLTRA Prescribing Information, reducing recommended monitoring time for the first two doses to 6-8 hours from 22-24 hours. This change aims to address practical barriers in administering IMDELLTRA and enable more patients to receive care closer to home.